7/12/2024  9:59:56 PM Chg. +0.70 Volume Bid- Ask- High Low
47.98USD +1.48% 56,389
Turnover: 2.68 mill.
-Bid Size: - -Ask Size: - 48.23 46.82

Business description

Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics in the United States. Its portfolio includes SPINRAZA, TEGSEDI, and WAYLIVRA for various genetic disorders. Additionally, it has multiple phase 3 studies underway for treatments addressing conditions like amyotrophic lateral sclerosis and cardiovascular disease. Headquarters: Carlsbad, California. Founded: 1989. Collaborations: Biogen, AstraZeneca, Novartis, and others.
 

Management board & Supervisory board

CEO
Brett P. Monia
Management board
Elizabeth L. Hougen, C. Frank Bennett, Onaiza Cadoret-Manier, Joseph T. Baroldi, Richard S. Geary, Patrick R. O’Neil, Eric E. Swayze, Eugene Schneider, Brian Birchler, Michael Yang
Supervisory board
Joseph Loscalzo, Brett P. Monia, Spencer R. Berthelsen, Allene M. Diaz, Michael Hayden, Joan E. Herman, Joseph Klein, B. Lynne Parshall, Joseph H. Wender
 

Company data

Name: Ionis Pharmaceuticals Inc.
Address: 2855 Gazelle Court,Carlsbad, CA 92010
Phone: +1-760-931-9200
Fax: -
E-mail: -
Internet: https://www.ionispharma.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 99.25%
IPO date: 1/1/1991

Investor relations

Name: -
IR phone: +1-760-603-2331
IR Fax: -
IR e-mail: info@ionisph.com

Main Shareholders